Analytical Data
-
Gene name
CBFA2T3
- Application
-
Alternative Names
MTG16; MTGR2; ZMYND4
-
Species
Human
-
Source
E. coli
-
Tag
Strep;His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75081-1
-
Expression Region
G170-S276
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CBFA2T3, also known as Core-binding factor subunit alpha-2 translocation protein 3, is a member of the CBF family of proteins, which are crucial in hematopoiesis and skeletal development. Research has highlighted its role as a transcriptional repressor, particularly in the context of various hematological malignancies. The CBFA2T3 gene is often implicated in chromosomal translocations, such as those seen in acute myeloid leukemia (AML) and other blood disorders, leading to the production of fusion proteins that disrupt normal gene regulation. Understanding the functional mechanisms of CBFA2T3 and its resultant protein interactions is essential for deciphering the pathways that contribute to oncogenesis. Recent studies have focused on the structural characterization of CBFA2T3 recombinant proteins to elucidate their biological roles and interactions. By producing and purifying recombinant CBFA2T3 proteins, researchers aim to investigate their effect on gene expression and identify potential therapeutic targets. These insights are critical for the development of novel treatment strategies for cancers associated with CBFA2T3 alterations, enhancing the potential for precision medicine in oncology.
